lumiracoxib versus 8/ 2159 patients (0.37%) for NSAIDs, with a HR of 1.14 [95% CI 0.44-2.95] p=0.7899.
9/ 2167 patsienti (0, 42%) lumirakoksiibi võtjate ning 8/ 2159 patsienti (0, 37%) MSPVA võtjate seas, riskisuhe HR oli 1, 14 [95% CI 0, 44… 2, 95] p=0, 7899.